Can-C™K9 Eye Drops

Can-C™ K9 is a high-quality formulation of N-Acetyl Carnosine, a highly specific intraocular (optical) form of carnosine which acts as both a stabiliser and carrier for safe delivery into the aqueous humour (gel-like contents of the eyeball) inside your pet's eyes. Once absorbed into the aqueous humour through the external covering of the eye, this bio-identical molecule becomes highly active in the reduction of free radicals, oxidative stress and lens glycosylation and has been laboratory-tested to reduce cataracts and other conditions which lead to Conjunctivitis and other issues.

Many dog owners (and even some vets) prefer to use using Can-C™ K9 to effectively treat their pet’s cataract condition and other problems, without resorting to surgery - which itself can lead to shorter-term beneficial outcomes, animal distress and large expense. The results of the original Russian clinical trials with dogs were promising and subsequent trials by the manufacturer, Profound Products, confirmed both effectiveness and the lack of serious negative side effects.

Amazingly, according to Dr. Babizhayev, the leading expert in this specialist field for both canines and humans, Can-C™ K9 appears to work even better in dogs than the similar Can-C™ does in humans as dogs lack the enzyme that tries (in humans) to restrict the full effectiveness of NAC.

The product is not approved by the FDA and hence the manufacturers do not claim it is a drug so remember to consult your veterinarian before administering natural remedies of any kind to your animals. Check our FDA section for more information on what this means.Our Can-C™K9 is backed by science and clinical studies that demonstrate its potential to improve canine ocular health. Healthy human and canine eyes naturally contain high levels of L-Carnosine, an essential antioxidant. However, in cases of degenerative ocular diseases like cataracts, these levels tend to be deficient. Can-C™K9 steps in to replenish the eye's natural reserves of this powerful antioxidant. The results are promising, as indicated by small-scale placebo-controlled clinical studies:

After 6 months of treatment, 90% of subjects showed improvements in visual acuity.

An impressive 89% experienced enhanced glare sensitivity.

42% observed an improvement in the transmissivity of the lens.

Importantly, these improvements persisted throughout the treatment duration.

For a more in-depth understanding of the scientific research and clinical trials supporting Can-C™K9, please explore our dedicated SCIENCE section.